Clinical Trial IDNCT04140526
Lead SponsorOncoImmune, Inc.
Principal Investigator
Start Date2020-02-01
Completion Date2023-02-01
Study TypeInterventional
PhasePhase 1
StatusNot yet recruiting

Purpose

This is a First-in-Human Phase IA/IB open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers.

Conditions

ConditionInterventionPhase
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate CancerDrug: ONC-392, Drug: PembrolizumabPhase 1

Eligibility

AgeGenderAccepts Healthy Volunteers
18 Years and older.AllNo